FDA Approves First All-Oral Therapy for CLL/SLL: Acalabrutinib & Venetoclax Regimen

The U.S. Food and Drug Administration (FDA) has approved a new first-line treatment option for adults with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The combination of acalabrutinib (Calquence) and venetoclax (Venclexta) is the first all-oral, fixed-duration regimen to receive approval for these blood cancers.

This approval, February 20, 2026, is based on data from the Phase 3 AMPLIFY trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to traditional chemoimmunotherapy. Specifically, the trial showed a 35% reduction in the risk of disease progression or death with the acalabrutinib-venetoclax combination (HR = 0.65; 95% CI, 0.49-0.87).

CLL is the most common type of leukemia in adults. Approximately 18,500 people in the U.S. Were treated for CLL in the first-line setting in 2024. For many patients, current treatment regimens involve continuous therapies, which can lead to cumulative side effects over time. This new combination offers a fixed-duration treatment option – 14 months – that may provide effective disease control while potentially minimizing long-term toxicities.

How the Treatment Works

Acalabrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, a targeted therapy that blocks a protein crucial for the survival of CLL cells. Venetoclax is a BCL-2 inhibitor, another targeted therapy that induces cancer cell death. By combining these two agents, the treatment aims to effectively eliminate cancer cells through different mechanisms.

In the AMPLIFY trial, patients were randomized to receive either acalabrutinib plus venetoclax, with or without obinutuzumab, or chemoimmunotherapy. The acalabrutinib-venetoclax combination was administered for a fixed duration of 14 cycles, with venetoclax initiated on the third cycle following a 5-week ramp-up schedule. Chemoimmunotherapy was given for six cycles.

Key Findings from the AMPLIFY Trial

At a median follow-up of 42.6 months, the median PFS was not reached in the acalabrutinib-venetoclax cohort (95% CI, 51.1 months-not reached), compared to 47.6 months (95% CI, 43.3-not reached) in the chemoimmunotherapy cohort. At a median follow-up of 41 months, fewer deaths were observed in the combination therapy group (6% vs. 14%).

Safety Profile

The most commonly reported adverse events in the acalabrutinib-venetoclax group included neutropenia (low white blood cell count), headache, diarrhea, and musculoskeletal pain. COVID-19 was also a common adverse event. Serious adverse events included COVID-19 pneumonia (9%), second primary malignancies (2.7%), and neutropenia (2.1%). Researchers reported no new safety signals during the trial.

What This Means for Patients

“The continuous regimens frequently used to treat chronic lymphocytic leukaemia often come with side effects that may become burdensome to patients over time,” said Jennifer Brown, MD, PhD, Director of the CLL Center of the Division of Hematologic Malignancies, Dana-Farber Cancer Institute, and principal investigator of the AMPLIFY trial. “The US approval of the Calquence combination offers patients an all-oral, 14-month, fixed-duration treatment option that is highly effective and well-tolerated, and gives physicians greater flexibility to tailor treatment plans for individual patient needs and goals.”

Svetlana Kobina, MD, PhD, vice president of global medical affairs at AbbVie Oncology, emphasized the significance of this approval, stating that it “expands choice and flexibility for patients and providers navigating complex treatment decisions in CLL.”

Recommended Dosage

The recommended regimen involves up to 14 cycles of acalabrutinib and 12 cycles of venetoclax, with venetoclax initiated on the third cycle. The recommended dose of acalabrutinib is 100 mg orally twice daily until disease progression, unacceptable toxicity, or completion of 14 cycles. Venetoclax is started at 20 mg with a 5-week ramp-up schedule, followed by a recommended dose of 400 mg once daily until disease progression, unacceptable toxicity, or the end of cycle 14.

This approval represents a significant advancement in the treatment of CLL and SLL, offering a new, all-oral, fixed-duration option that may improve outcomes and quality of life for patients.